SCHEMBL19969869

SCHEMBL19969869

CC(C)CCC(C)CC(C)NC(C)C

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.33
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19080590 0.78 TDP1 (0.41) TDP1LMNA
SCHEMBL19121759 0.77 LMNA (0.32) LMNA
SCHEMBL20921769 0.77 LMNA (0.32) LMNA
SCHEMBL20099378 0.76 ADH1B (0.32) TDP1
SCHEMBL12703373 0.75 TDP1 (0.44) TDP1LMNA
SCHEMBL13995936 0.75 TDP1 (0.44) TDP1LMNA
SCHEMBL13995874 0.75 TDP1 (0.44) TDP1LMNA
SCHEMBL19969956 0.75 SLC6A4 (0.33)
SCHEMBL19986440 0.74 TDP1 (0.50) TDP1
SCHEMBL24288643 0.74 TDP1 (0.37) TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180072758-A1 5HT3 RECEPTOR ANTAGONISTS TAKEDA CALIFORNIA, INC. 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180072758-A1 5HT3 RECEPTOR ANTAGONISTS HTR3A, HTR3B, HTR5A TDP1 2555/4885LMNA 3514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.